Published in J Alzheimers Dis on January 01, 2011
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain (2011) 1.55
Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations. Drug Des Devel Ther (2014) 0.93
Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement (2014) 0.90
Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD). Brain Struct Funct (2014) 0.86
Age-related neurodegeneration and memory loss in down syndrome. Curr Gerontol Geriatr Res (2012) 0.83
Designer receptors enhance memory in a mouse model of Down syndrome. J Neurosci (2015) 0.82
Dissecting Alzheimer disease in Down syndrome using mouse models. Front Behav Neurosci (2015) 0.79
Noradrenergic dysfunction in Alzheimer's disease. Front Neurosci (2015) 0.78
The use of mouse models for understanding the biology of down syndrome and aging. Curr Gerontol Geriatr Res (2012) 0.77
Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome. Curr Alzheimer Res (2016) 0.77
Estrogen receptor alpha deficiency protects against development of cognitive impairment in murine lupus. J Neuroinflammation (2014) 0.77
Report and Research Agenda of the American Geriatrics Society and National Institute on Aging Bedside-to-Bench Conference on Sleep, Circadian Rhythms, and Aging: New Avenues for Improving Brain Health, Physical Health, and Functioning. J Am Geriatr Soc (2016) 0.75
Mouse-based genetic modeling and analysis of Down syndrome. Br Med Bull (2016) 0.75
Maternal choline supplementation in a mouse model of Down syndrome: Effects on attention and nucleus basalis/substantia innominata neuron morphology in adult offspring. Neuroscience (2016) 0.75
The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS (1988) 6.75
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A (1989) 5.97
Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron (2006) 3.51
Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci (2006) 2.85
Memory reconsolidation: sensitivity of spatial memory to inhibition of protein synthesis in dorsal hippocampus during encoding and retrieval. Neuron (2006) 2.75
Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med (2009) 1.94
Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog Clin Biol Res (1990) 1.84
Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol (2000) 1.80
Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci (2006) 1.79
Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci U S A (2001) 1.72
A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci Lett (1995) 1.70
Disease-specific patterns of locus coeruleus cell loss. Ann Neurol (1992) 1.64
Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev (2004) 1.63
Locus coeruleus and regulation of behavioral flexibility and attention. Prog Brain Res (2000) 1.62
Differential expression of plasticity-related genes in waking and sleep and their regulation by the noradrenergic system. J Neurosci (2000) 1.60
Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat (2003) 1.50
Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci (2006) 1.46
Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies. Neurology (2003) 1.46
Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci (2002) 1.46
Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging (2006) 1.43
Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol (1989) 1.37
Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp Neurol (2000) 1.35
TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. J Comp Neurol (1994) 1.26
Loss of calbindin-D28k from aging human cholinergic basal forebrain: relation to neuronal loss. J Comp Neurol (2003) 1.25
A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp Neurol (2006) 1.23
Behavioral comparison of 4 and 6 month-old Ts65Dn mice: age-related impairments in working and reference memory. Behav Brain Res (2003) 1.21
Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behav Brain Res (2003) 1.20
Motor dysfunction in a mouse model for Down syndrome. Physiol Behav (2000) 1.19
Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int (2002) 1.17
Abnormalities of the nucleus basalis in Down's syndrome. Ann Neurol (1985) 1.11
Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging (2006) 1.11
Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J Chem Neuroanat (2007) 1.11
Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J Neurochem (2010) 1.10
Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann Neurol (2004) 1.07
Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol (2008) 1.06
Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord (1987) 1.06
Functional evidence that BDNF is an anterograde neuronal trophic factor in the CNS. J Neurosci (1998) 1.05
Experimental parameters affecting the Morris water maze performance of a mouse model of Down syndrome. Behav Brain Res (2004) 1.04
Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. J Neurosci (1992) 1.04
Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. J Pharmacol Exp Ther (1997) 1.02
Constitutive overexpression of Cu/Zn superoxide dismutase exacerbates kainic acid-induced apoptosis of transgenic-Cu/Zn superoxide dismutase neurons. Proc Natl Acad Sci U S A (1996) 0.99
The influence of specific noradrenergic and serotonergic lesions on the expression of hippocampal brain-derived neurotrophic factor transcripts following voluntary physical activity. Neuroscience (2003) 0.97
The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells. Neuropsychopharmacology (2006) 0.96
Understanding mental retardation in Down's syndrome using trisomy 16 mouse models. Genes Brain Behav (2003) 0.95
Multiple evidence for an early age pro-oxidant state in Down Syndrome patients. Biogerontology (2006) 0.94
Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. J Neurochem (2006) 0.93
Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen. Neurobiol Aging (2004) 0.93
Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome. Neurosci Res (2003) 0.92
Learning and memory as a function of age in Down syndrome: a study using animal-based tasks. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.92
Retrograde transport of brain-derived neurotrophic factor (BDNF) following infusion in neo- and limbic cortex in rat: relationship to BDNF mRNA expressing neurons. J Comp Neurol (1996) 0.91
Effects of concurrent manipulations of cholinergic and noradrenergic function on learning and retention in mice. Brain Res (1989) 0.91
Effects of acute and subchronic administration of dexefaroxan, an alpha(2)-adrenoceptor antagonist, on memory performance in young adult and aged rodents. J Pharmacol Exp Ther (2002) 0.87
Region- and neurotransmitter-dependent species and strain differences in DSP-4-induced monoamine depletion in rodents. Neurodegeneration (1996) 0.86
Retrograde changes in cholinergic neurons in the basal forebrain of the rat following cortical damage. Brain Res (1983) 0.86
Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1. Neurobiol Dis (2004) 0.86
Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome. Brain Res (1997) 0.84
The interaction of the beta-haloethyl benzylamines, xylamine, and DSP-4 with catecholaminergic neurons. Annu Rev Pharmacol Toxicol (1990) 0.83
Calcium binding protein (calbindin-D28k) and glutamate decarboxylase gene expression after kindling induced seizures. Brain Res Mol Brain Res (1991) 0.82
Evidence that brain-derived neurotrophic factor from presynaptic nerve terminals regulates the phenotype of calbindin-containing neurons in the lateral septum. J Neurosci (2000) 0.82
Repeated administration of the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) modulates neuroinflammation and amyloid plaque load in mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. J Neuroinflammation (2007) 0.81
Regulation of trophic factor expression by innervating target regions in intraocular double transplants. Cell Transplant (2005) 0.77
Potentiation by DSP-4 of EEG slowing and memory impairment in basal forebrain-lesioned rats. Eur J Pharmacol (1997) 0.76
A role for lateral hypothalamic orexin neurons in reward seeking. Nature (2005) 5.41
Decision making, the P3, and the locus coeruleus-norepinephrine system. Psychol Bull (2005) 3.97
Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA (2002) 3.16
Arousal and reward: a dichotomy in orexin function. Trends Neurosci (2006) 2.79
Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol (2003) 2.56
Linking context with reward: a functional circuit from hippocampal CA3 to ventral tegmental area. Science (2011) 2.48
Activation of ventral tegmental area cells by the bed nucleus of the stria terminalis: a novel excitatory amino acid input to midbrain dopamine neurons. J Neurosci (2002) 2.00
Lateral hypothalamic orexin neurons are critically involved in learning to associate an environment with morphine reward. Behav Brain Res (2007) 1.73
Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking. Eur J Neurosci (2009) 1.67
Critical role for ventral tegmental glutamate in preference for a cocaine-conditioned environment. Neuropsychopharmacology (2003) 1.60
Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct Funct (2008) 1.54
Phasic activation of monkey locus ceruleus neurons by simple decisions in a forced-choice task. J Neurosci (2004) 1.51
Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity. Physiol Behav (2010) 1.50
Neurocognitive impairment in obstructive sleep apnea. Chest (2012) 1.50
Progesterone reverses the spatial memory enhancements initiated by tonic and cyclic oestrogen therapy in middle-aged ovariectomized female rats. Eur J Neurosci (2006) 1.44
Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol (2002) 1.37
Orexin/hypocretin is necessary for context-driven cocaine-seeking. Neuropharmacology (2009) 1.29
Altered motivation and learning following opiate withdrawal: evidence for prolonged dysregulation of reward processing. Neuropsychopharmacology (2003) 1.26
Multiple roles for orexin/hypocretin in addiction. Prog Brain Res (2012) 1.26
Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). Neuropsychopharmacology (2010) 1.25
Selective loss of catecholaminergic wake active neurons in a murine sleep apnea model. J Neurosci (2007) 1.21
Enhanced morphine preference following prolonged abstinence: association with increased Fos expression in the extended amygdala. Neuropsychopharmacology (2003) 1.19
Environmental influences on brain neurotrophins in rats. Pharmacol Biochem Behav (2002) 1.17
Adrenergic and noradrenergic innervation of the midbrain ventral tegmental area and retrorubral field: prominent inputs from medullary homeostatic centers. J Neurosci (2009) 1.15
Role of the bed nucleus of the stria terminalis in the control of ventral tegmental area dopamine neurons. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.15
α(2) Adrenergic and imidazoline receptor agonists prevent cue-induced cocaine seeking. Biol Psychiatry (2011) 1.15
Activation of monkey locus coeruleus neurons varies with difficulty and performance in a target detection task. J Neurophysiol (2004) 1.15
Interactions between VTA orexin and glutamate in cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berl) (2012) 1.15
Designer receptor manipulations reveal a role of the locus coeruleus noradrenergic system in isoflurane general anesthesia. Proc Natl Acad Sci U S A (2014) 1.13
Orexin-1 receptor antagonism decreases ethanol consumption and preference selectively in high-ethanol--preferring Sprague--Dawley rats. Alcohol (2009) 1.13
Synaptic glutamate spillover due to impaired glutamate uptake mediates heroin relapse. J Neurosci (2014) 1.12
Activation in extended amygdala corresponds to altered hedonic processing during protracted morphine withdrawal. Behav Brain Res (2006) 1.10
Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res (2010) 1.09
Circuit projection from suprachiasmatic nucleus to ventral tegmental area: a novel circadian output pathway. Eur J Neurosci (2008) 1.08
No effect of morphine on ventral tegmental dopamine neurons during withdrawal. J Neurosci (2006) 1.08
Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. J Neurosci (2007) 1.07
Orexin/hypocretin modulates response of ventral tegmental dopamine neurons to prefrontal activation: diurnal influences. J Neurosci (2010) 1.07
Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann Neurol (2004) 1.07
Use of seniors as mentors to medical students: a collaboration between the University of South Carolina School of Medicine and the Medical University of South Carolina. J S C Med Assoc (2011) 1.07
Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol (2008) 1.06
Role of orexin/hypocretin in conditioned sucrose-seeking in rats. Psychopharmacology (Berl) (2012) 1.05
Damaging effects of a high-fat diet to the brain and cognition: a review of proposed mechanisms. Nutr Neurosci (2013) 1.03
Endotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits. Neurotoxicology (2008) 1.03
The behavioral economics of drug self-administration: a review and new analytical approach for within-session procedures. Psychopharmacology (Berl) (2012) 1.02
Halothane-induced hypnosis is not accompanied by inactivation of orexinergic output in rodents. Anesthesiology (2009) 1.00
Orexin / hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur J Neurosci (2012) 0.99
Circadian regulation of arousal: role of the noradrenergic locus coeruleus system and light exposure. Sleep (2006) 0.97
Role of orexin input in the diurnal rhythm of locus coeruleus impulse activity. Brain Res (2008) 0.97
Nerve growth factor in treatment and pathogenesis of Alzheimer's disease. Prog Neurobiol (2006) 0.97
Targeted over-expression of glutamate transporter 1 (GLT-1) reduces ischemic brain injury in a rat model of stroke. PLoS One (2011) 0.96
Age-dependent loss of NGF signaling in the rat basal forebrain is due to disrupted MAPK activation. Neurosci Lett (2006) 0.96
Prolonged activation of mesolimbic dopaminergic neurons by morphine withdrawal following clonidine: participation of imidazoline and norepinephrine receptors. Neuropsychopharmacology (2003) 0.94
The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease. Front Behav Neurosci (2012) 0.93
Mood, memory and movement: an age-related neurodegenerative complex? Curr Aging Sci (2008) 0.93
Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen. Neurobiol Aging (2004) 0.93
Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome. Neurosci Res (2003) 0.92
Use of vivo-morpholinos for control of protein expression in the adult rat brain. J Neurosci Methods (2011) 0.91
PTEN deletion enhances survival, neurite outgrowth and function of dopamine neuron grafts to MitoPark mice. Brain (2012) 0.91
Regulation of the ventral tegmental area by the bed nucleus of the stria terminalis is required for expression of cocaine preference. Eur J Neurosci (2012) 0.91
Cognitive neuroscience: decision amid uncertainty. Nature (2005) 0.91
Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med (2010) 0.89
Modafinil attenuates reinstatement of cocaine seeking: role for cystine-glutamate exchange and metabotropic glutamate receptors. Addict Biol (2012) 0.89
Modafinil blocks reinstatement of extinguished opiate-seeking in rats: mediation by a glutamate mechanism. Neuropsychopharmacology (2010) 0.88
Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets (2004) 0.87
Minocycline protects basal forebrain cholinergic neurons from mu p75-saporin immunotoxic lesioning. Eur J Neurosci (2004) 0.87
Diet-induced effects on neuronal and glial elements in the middle-aged rat hippocampus. Nutr Neurosci (2011) 0.86
Lateral hypothalamic orexin/hypocretin neurons that project to ventral tegmental area are differentially activated with morphine preference. J Neurosci (2012) 0.86
Simplified dynamics in a model of noradrenergic modulation of cognitive performance. Neural Netw (2002) 0.86
A dual-hit animal model for age-related parkinsonism. Prog Neurobiol (2009) 0.85
Enhanced dopamine transporter activity in middle-aged Gdnf heterozygous mice. Neurobiol Aging (2010) 0.85
3-Monoiodothyronamine: the rationale for its action as an endogenous adrenergic-blocking neuromodulator. Brain Res (2010) 0.85
Intact cognition in depressed elderly veterans providing adequate effort. Arch Clin Neuropsychol (2011) 0.84
Preliminary examination of progression of Alzheimer's disease in a rural Southern African American cohort. Arch Clin Neuropsychol (2007) 0.84
Orexin-1 receptor signaling increases motivation for cocaine-associated cues. Eur J Neurosci (2015) 0.83
Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). Am J Geriatr Psychiatry (2013) 0.83
Measurement of plasma ammonia is affected in patients receiving asparaginase therapy. Clin Chem (2003) 0.83
Minocycline restores striatal tyrosine hydroxylase in GDNF heterozygous mice but not in methamphetamine-treated mice. Neurobiol Dis (2008) 0.83
Blueberry extract enhances survival of intraocular hippocampal transplants. Cell Transplant (2005) 0.82
Attenuation of saccharin-seeking in rats by orexin/hypocretin receptor 1 antagonist. Psychopharmacology (Berl) (2013) 0.82
New tricks for old dogmas: optogenetic and designer receptor insights for Parkinson's disease. Brain Res (2013) 0.81
Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion. Cell Transplant (2002) 0.81
Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFR alpha1, gene. Brain Res (2008) 0.81
Nerve growth factor metabolic dysfunction in Down's syndrome brains. Brain (2014) 0.81
Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF. Pharmacol Biochem Behav (2013) 0.80
The nigrostriatal dopamine system of aging GFRalpha-1 heterozygous mice: neurochemistry, morphology and behavior. Eur J Neurosci (2008) 0.80
Blueberry supplementation attenuates microglial activation in hippocampal intraocular grafts to aged hosts. Glia (2010) 0.80
Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res (2006) 0.80
In vivo modulation of nitric oxide concentration dynamics upon glutamatergic neuronal activation in the hippocampus. Hippocampus (2010) 0.80
Altered NGF response but not release in the aged septo-hippocampal cholinergic system. Exp Neurol (2005) 0.80
APOE genotype in the diagnosis of Alzheimer's disease in patients with cognitive impairment. Am J Alzheimers Dis Other Demen (2012) 0.79
The influence of spike rate and stimulus duration on noradrenergic neurons. J Comput Neurosci (2004) 0.79
Repeated orexin 1 receptor antagonism effects on cocaine seeking in rats. Neuropharmacology (2012) 0.78
Effects of glial cell line-derived neurotrophic factor deletion on ventral mesencephalic organotypic tissue cultures. Brain Res (2006) 0.78
Modafinil: an anti-relapse medication. Neuropsychopharmacology (2010) 0.78
The highly selective orexin/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice. Brain Res (2016) 0.78
Special issue on neuropeptides in stress and addiction: Overview. Brain Res (2010) 0.77
Improved methods for electroacupuncture and electromyographic recordings in normal and parkinsonian rhesus monkeys. J Neurosci Methods (2010) 0.77
Globus pallidus plays a critical role in neurotrophic factor induced functional improvements in hemiparkinsonian monkeys. Biochem Biophys Res Commun (2008) 0.77